Vanda Pharmaceuticals (VNDA) Competitors $4.81 -0.01 (-0.21%) Closing price 04:00 PM EasternExtended Trading$4.77 -0.04 (-0.83%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VNDA vs. GERN, INVA, MYGN, RIGL, VSTM, EBS, IRWD, XOMA, CDXS, and SGMOShould you be buying Vanda Pharmaceuticals stock or one of its competitors? The main competitors of Vanda Pharmaceuticals include Geron (GERN), Innoviva (INVA), Myriad Genetics (MYGN), Rigel Pharmaceuticals (RIGL), Verastem (VSTM), Emergent BioSolutions (EBS), Ironwood Pharmaceuticals (IRWD), XOMA (XOMA), Codexis (CDXS), and Sangamo Therapeutics (SGMO). These companies are all part of the "biotechnology" industry. Vanda Pharmaceuticals vs. Geron Innoviva Myriad Genetics Rigel Pharmaceuticals Verastem Emergent BioSolutions Ironwood Pharmaceuticals XOMA Codexis Sangamo Therapeutics Geron (NASDAQ:GERN) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations, community ranking and media sentiment. Do institutionals & insiders have more ownership in GERN or VNDA? 73.7% of Geron shares are owned by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. 3.1% of Geron shares are owned by company insiders. Comparatively, 8.9% of Vanda Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community believe in GERN or VNDA? Vanda Pharmaceuticals received 42 more outperform votes than Geron when rated by MarketBeat users. However, 70.03% of users gave Geron an outperform vote while only 66.26% of users gave Vanda Pharmaceuticals an outperform vote. CompanyUnderperformOutperformGeronOutperform Votes50070.03% Underperform Votes21429.97% Vanda PharmaceuticalsOutperform Votes54266.26% Underperform Votes27633.74% Which has better valuation & earnings, GERN or VNDA? Vanda Pharmaceuticals has higher revenue and earnings than Geron. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Geron, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGeron$76.99M14.48-$184.13M-$0.27-6.48Vanda Pharmaceuticals$198.77M1.41-$18.90M-$0.32-15.06 Is GERN or VNDA more profitable? Vanda Pharmaceuticals has a net margin of -9.51% compared to Geron's net margin of -682.48%. Vanda Pharmaceuticals' return on equity of -3.49% beat Geron's return on equity.Company Net Margins Return on Equity Return on Assets Geron-682.48% -67.53% -45.46% Vanda Pharmaceuticals -9.51%-3.49%-2.90% Does the media refer more to GERN or VNDA? In the previous week, Geron had 33 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 33 mentions for Geron and 0 mentions for Vanda Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 1.46 beat Geron's score of 0.13 indicating that Vanda Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Geron Neutral Vanda Pharmaceuticals Positive Do analysts recommend GERN or VNDA? Geron currently has a consensus target price of $5.75, suggesting a potential upside of 228.57%. Vanda Pharmaceuticals has a consensus target price of $16.50, suggesting a potential upside of 242.32%. Given Vanda Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Vanda Pharmaceuticals is more favorable than Geron.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Geron 0 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.82Vanda Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, GERN or VNDA? Geron has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500. Comparatively, Vanda Pharmaceuticals has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. SummaryVanda Pharmaceuticals beats Geron on 12 of the 19 factors compared between the two stocks. Remove Ads Get Vanda Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VNDA vs. The Competition Export to ExcelMetricVanda PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$281.08M$7.13B$5.74B$8.28BDividend YieldN/A2.72%4.55%4.02%P/E Ratio-15.067.3324.7219.36Price / Sales1.41239.38398.2493.27Price / CashN/A65.6738.1634.64Price / Book0.526.787.154.51Net Income-$18.90M$142.41M$3.20B$247.14M7 Day Performance-3.41%5.03%2.83%3.64%1 Month Performance8.07%4.47%6.98%-2.30%1 Year Performance24.55%-3.29%15.58%4.92% Vanda Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VNDAVanda Pharmaceuticals4.6013 of 5 stars$4.81-0.2%$16.50+243.0%+23.9%$280.50M$198.77M-15.03290Positive NewsGERNGeron4.324 of 5 stars$1.74+6.1%$5.75+230.5%-47.1%$1.11B$76.99M-5.4470INVAInnoviva4.3146 of 5 stars$17.53+0.8%$55.00+213.7%+14.8%$1.10B$358.71M25.41100Analyst UpgradePositive NewsMYGNMyriad Genetics4.2552 of 5 stars$10.12+0.5%$21.89+116.3%-55.1%$924.05M$837.60M-7.782,700RIGLRigel Pharmaceuticals3.0108 of 5 stars$21.03+4.5%$36.80+75.0%+44.6%$375.66M$179.28M150.23160Positive NewsVSTMVerastem3.0894 of 5 stars$7.23+3.9%$13.63+88.5%-42.9%$321.79M$10M-2.2750Earnings ReportAnalyst ForecastNews CoverageEBSEmergent BioSolutions4.1384 of 5 stars$5.78+1.1%$14.33+148.2%+138.0%$313.80M$1.01B-1.411,600Analyst RevisionIRWDIronwood Pharmaceuticals4.0565 of 5 stars$1.54+3.4%$8.60+458.4%-82.8%$246.44M$351.41M-51.33220Analyst RevisionXOMAXOMA4.0663 of 5 stars$20.73+1.4%$72.00+247.3%-15.6%$244.26M$9.71M-5.9610CDXSCodexis3.9938 of 5 stars$2.92+5.0%$8.33+185.4%-11.0%$241.88M$59.35M-3.36250News CoverageSGMOSangamo Therapeutics2.4262 of 5 stars$1.01+2.9%$5.80+474.3%+23.8%$210.73M$52.29M-1.35480 Remove Ads Related Companies and Tools Related Companies Geron Competitors Innoviva Competitors Myriad Genetics Competitors Rigel Pharmaceuticals Competitors Verastem Competitors Emergent BioSolutions Competitors Ironwood Pharmaceuticals Competitors XOMA Competitors Codexis Competitors Sangamo Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VNDA) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vanda Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vanda Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VNDA Stock Free VNDA Stock Alerts